Integrin Beta 4 Protein Expression Bimodally Predicts Sensitivity to CDK4/6 Inhibition and Resistance to Immunotherapy in Breast Cancer

Key Points

• To evaluate the role of ITGB4 protein expression as a biomarker in predicting treatment sensitivity in breast cancer.
• Assessment of ITGB4 protein expression levels in breast cancer subtypes.
• Evaluation of sensitivity to CDK4/6 inhibitors in luminal subtypes.
• Analysis of immunotherapy resistance in triple-negative breast cancer (TNBC).
• ITGB4 expression predicts sensitivity to CDK4/6 inhibitors in luminal breast cancer subtypes.
• High ITGB4 levels indicate resistance to immunotherapy in TNBC.
• ITGB4 serves as a critical biomarker for personalized therapy.